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We thank Drs Forte and Della Corte
for their insightful comments and the
opportunity to clarify a number of
points from our work. We agree with
the authors of the letter that the mecha-
nisms driving aortic dilation in bicuspid
aortic valve (BAV) and tricuspid aortic
valve (TAV) are different but not as yet
explained. Along that line, also based
on the expertise of most of our authors,
we hypothesized that a developmental
background linking BAV and the
accompanying aortic wall might
provide new insights into the matter.
Hemodynamic differences could still
play a role in the developing patho-
biology but might not be the primary
insult.
This approach led to different
selection criteria for our patient
population. We did not primarily
take into account the presence
of aortic stenosis/regurgitation but
focused on nondilation (<45 mm)
and dilation of the aortic wall within
the BAV and TAV groups. Additional
characteristics of our study population
are presented in Table 1, which
also provides answers to a number
of questions with regard to the
material studied. The aortic valve pa-
thology in nondilated and dilated
BAV and dilated TAV varied between
either stenosis or no stenosis, with or
without regurgitation. In dilated
BAV and TAV, in some cases only an2440 The Journal of Thoracic andascending aorta replacement was
performed because there was no aortic
root pathology that needed surgical
correction. All biopsy specimens
were taken from the ascending
aortic wall adjoining the surgical
transverse aortotomy site. In case of
post mortem or transplant material,
the tissue was taken at identical
sites. The results of Forte and col-
leagues1 and our publication2 can in
part be appreciated as complementary.
Some differences need an additional
explanation from our side, as provided
here.
The described results in expression
of a-smooth muscle actin in the article
of Forte and colleagues1 and our study
do indeed not correlate. This is
most probably due to a difference
of technique in which messenger
RNA expression based on reverse
transcriptase polymerase chain
reaction analysis of the vascular
wall1 was compared with our
immunohistochemical examination
of the 3 vessel wall layers.2 In
case of increased messenger RNA
detection, a lowered translation into
protein can not be excluded. Drs Forte
and Della Corte are correct that
almost absent smoothelin expression
cannot be detected by immuno-
histochemical means, so we agree
with their results that smoothelin
expression is lowered, which
correlates with an immature smooth
muscle cell phenotype.3,4 With
regard to the cellular composition of
the media and intima of the aortic
wall, we do not postulate a few
resident fibroblasts to be present that,
under experimental development of
thoracic aortic dilation, replace the
disappearing smooth muscle cell
population by myofibroblasts, as
indicated by Jones and associates5
and accepted by Forte and
colleagues.1 In our studies, it suffices
to have a mature contractile smooth
muscle cell phenotype that can switch
to a synthetic (immature) phenotype
that expresses most of the markersCardiovascular Surgery c November 20also attributed to the myofibroblast
phenotype, including the fibronectin
splice variants.6 Our assumption
is supported by less apoptosis
(caspase-3) in the wall of the nondi-
lated as well as the dilated BAV
(unpublished data). Apoptosis was,
however, detected (not shown) in the
media of the dilated TAV and was in
our study2 linked to the increased
expression of progerin. Regarding
this aspect, we will have further
comments when discussing the aspect
of aging.
As described previously, our study
population was primarily not selected
on the valve pathology or on the
difference in architecture of the
convex versus concave site. The fact
that our group consisted of patients
with a nondilated versus a dilated
aortic wall, with variable aortic
valve pathology and commissure
position, underlines that the observed
differences between all BAVs and
TAVs are intrinsic to the BAV wall
morphology. This is further supported
in a recently accepted article7 in
which we did address the differences
between the convex and concave
aortic sites of patients with a dilated
aortic wall, provided by our
German coauthors who have adopted
the selection technique described
previously.8 We did not disclaim the
earlier published differences8,9 in the
structure of the wall and the
expressions of markers between
the convex and concave site of
the aorta. We did, however perform,
an additional analysis on these
specimens with transforming growth
factor-b and endothelial nitric oxide
and found no difference in
expression between the convex and
concave sites.7 Hemodynamic influ-
ences are therefore not excluded
from having an important influence
but according to our studies cannot
be considered as the primary source
for the observed differences in
dilation formation between BAV
and TAV.14
TABLE 1. Additional characteristics of the study population
Characteristic TA (n ¼ 11) TAD (n ¼ 12) BA (n ¼ 17) BAD (n ¼ 19)
Specimen obtained Post mortem, LUMC During elective repair of
ascending aorta, LUMC
During stentless root
replacement, collected
residue material from
proximal anastomosis,
LUMC and 6 biopsies, EMC
During elective repair of
ascending aorta, LUMC
Age (y, mean  SD) 64.5  9.0 72.3  11.2 55.8  9.8 60.7  7.8
Male (%) 54.5 33.3 70.1 84.2
Female (%) 45.5 66.7 29.4 15.8
Ascending aortic diameter
(mm, mean  SD)
* 55.0  10.7 36.5  7.4y 52.7  6.2
Commissure position Unicuspid, n ¼ 1; RCC/LCC, n
¼ 8;
RCC/NCC, n ¼ 4; LCC/NCC,
n ¼ 1;
unknown, n ¼ 3
RCC/LCC, n ¼ 15;
unknown, n ¼ 4
TA, Nondilated tricuspid aortic valve; TAD, dilated tricuspid aortic valve; BA, nondilated bicuspid aortic valve; BAD, dilated bicuspid aortic valve; LUMC, Leiden University
Medical Center; EMC, Erasmus Medical Center; RCC/LCC, fusion of the right and left coronary cusps; RCC/NCC, fusion of the right coronary and noncoronary cusps;
LCC/NCC, fusion of the left coronary and noncoronary cusps; SD, standard deviation. *Data unavailable, clinically defined as nondilated by pathologist. yData unavailable
for 5 patients, clinically defined as nondilated by pathologist.
Letters to the EditorOn basis of these observations and
additional arguments provided here,
we cannot endorse the concluding
remarks of Drs Forte and Della
Corte: ‘‘Functionally, one of the
early signs of arterial aging is
impaired wall distensibility, which
is known to occur in the BAV aorta,
even before overt dilation. Thus
with the currently available data, a
hypothesis of defective wall matura-
tion is hardly sustainable, without
ruling out the contribution of flow
induced remodeling. A conceptually
opposite theory of premature aging
of the aortic wall, prompted by
altered biomechanical environment,
could be drawn as well.’’ In this
respect, the definition and detection
of aging of the vascular wall are an
issue. Loss of aortic wall distensi-
bility, which is based on the increase
of collagen and loss of elastin, is
considered by some to represent a
measure of vascular wall aging5 and
used not only for the TAV models
but also for BAV.1 We have not speci-
fically studied the collagen content,
but we do confirm the diminished
elastin structure in BAV.2 Addition-
ally, we have introduced a new set
of aging markers encompassing the
balance between lamin A/C andThe Journalprogerin.2,10 Even physiologic
aging with increasing calendar age
has been correlated with the
increased expression of progerin.10-
12 We are excited about the fact that
in this way we could differentiate
between TAV and BAV, showing
increased physiologic aging in
TAV on the basis of an increase
of progerin and accompanying
apoptosis resulting in cytolytic
necrosis, although this finding was
lacking in BAV. The decrease of
distensibility as described1,5 might
still hold for the aortopathy in both
BAV and TAV but should in our
opinion not be translated as an
indication of premature aging in
BAV. In our study we had the
relatively unique opportunity to
show that the structural immaturity
was present in both nondilated and
dilated BAVs, independent of the
degree and type of underlying aortic
valve pathology.
In conclusion we demonstrated
that a different mechanism underlies
aortic dilation in BAV and TAV.
We postulate that secondarily hemo-
dynamic influences, additionally
triggered by the specific BAV aortic
valve pathology, might have a
different impact on the immatureof Thoracic and Cardiovascular SurgerBAV wall as opposed to the aging
TAV aortic wall.
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BIATRIAL COX MAZE IV: WE
ARE GOING IN THE RIGHT
DIRECTION
To the Editor:
I read with great interest the article
by Lawrance and colleagues,1 and I
congratulate them on this very
interesting and well-written article.
They have shown that the Cox maze
IV procedure, with its inherent
variations, can be performed bymeans2442 The Journal of Thoracic andof a less invasive right anterolateral
minithoracotomy with excellent
outcome. My personal preference is
for the classic standard ‘‘cut-and-
sew’’ Cox maze III procedure. Once
the surgeon has acquired technical
expertise, this procedure is both easy
and safe to do. What is truly important
is not the complexity of the procedure,
but rather the aortic crossclamp time.
This is the rub, and this is why
alternative energy sources for atrial
fibrillation surgery have mushroomed
in recent years. Since 2002, this
has been termed as Cox maze IV
procedure. Damiano and his working
group2 have been pioneers in this
technology. The idea proposed by
Lawrance and colleagues1 looks
promising. In addition to the mini-
mally invasive surgery, they used the
only 2 energy sources that have been
proved to be successful achieving
full transmural lesions in the atria,
bipolar radiofrequency and cryole-
sion. This great effort by Lawrance
and colleagues1 in this article high-
lights that the trend is now toward
the idea conceived by Cox3 11 years
ago. He stated that surgery for atrial
fibrillation should meet the following
conditions: (1) the procedure should
preferably be epicardial by nature;
(2) the energy source should be
capable of penetrating epicardial fat
and ablating all types of atrial fibrilla-
tion; (3) cardiopulmonary bypass
must be avoided; (4) the procedure
should be amenable to endoscopic or
minimally invasive techniques; (5) it
should be performed in less than 1
hour; and (6) hospital discharge
should be possible on the first
postoperative day. Although it is true
that not all these objectives have
been achieved, we must recognize
that we are on the right track. Novel
devices are being developed4,5; as
yet, however, transmural lesions
have not been safely produced on the
beating heart by epicardial ablation.
Unfortunately, cardiopulmonary by-
pass remains a crucial aspect to
perform this kind of procedure. TheCardiovascular Surgery c November 20most important point is that we are
going on the right direction, each
moment getting closer to the goal. I
really congratulate Lawrance and
colleagues1 for this fine and great
effort.
Ovidio A. Garcia-Villarreal, MD
Department of Cardiac Surgery
Hospital of Cardiology UMAE 34
Instituto Mexicano del Seguro Social
Monterrey, MexicoReferences
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POLYTETRAFLUOROETHY-
LENE NEOCHORDAE USED
FOR MITRALVALVE REPAIR:
DOES SIZE MATTER?
To the Editor:
In a report published in another
journal in 2007,1 we reported 2 cases
of rupture of synthetic chordae tendi-
neae (expanded polytetrafluoroethylene
[ePTFE]).Wealso analyzed thepossible
causes of what was then considered an
extremely rare finding, which had first
been reported by Buttany and14
